A partial sequence of the NS5 gene showed that the Zika virus isolate from this patient was closely related to those described elsewhere in the Western Hemisphere belonging to the Asian lineage, particularly to 2 strains identified in Brazil and Suriname during 2015.

Acknowledgments

We thank the staff of the Molecular Biology and Virology Departments, INTURE for technical assistance. We also thank Jose Gudiño (Queretaro Public Health Laboratory) for sending serum sample for analysis.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official opinion of the Ministry of Health of Mexico.

References


Address for correspondence: José Alberto Díaz-Quíñonez, Instituto de Diagnóstico y Referencia Epidemiológicos “Dr. Manuel Martínez Báez,” Francisco de P. Miranda 177, Col. Lomas de Plateros, C. P. 01480, Alvaro Obregón, Mexico City, Mexico; email: alberto.diaz@salud.gob.mx

Technological Solutions to Address Drug-Resistant Neisseria gonorrhoeae

Claire C. Bristow, Huan Dong, Jeffrey D. Klausner

Author affiliations: University of California San Diego, La Jolla, California, USA (C.C. Bristow); Charles R. Drew University of Medicine and Science, Los Angeles, California, USA (H. Dong); University of California Los Angeles, Los Angeles, Los Angeles (H. Dong, J.D. Klausner)

DOI: http://dx.doi.org/10.3201/eid2205.160083

To the Editor: Since the 1930s, Neisseria gonorrhoeae has become resistant to drugs in every class of antimicrobial therapy used to treat it. We read with interest the article by Martin et al. about trends in Canada on N. gonorrhoeae susceptibility to third-generation cephalosporins, the only class of antimicrobial drugs to which most N. gonorrhoeae strains remain susceptible (1). We find the reported decrease in cefixime- and ceftriaxone-reduced susceptibility during 2010–2014 encouraging, but remain concerned about a threat from drug-resistant and untreatable N. gonorrhoeae infections: a similar downward trend in the United States reversed in 2014 (2). That divergence demonstrates the limited reliability of surveillance data.

Addressing resistance requires new methods for susceptibility determination without culture. Real-time screening for genes associated with antimicrobial drug resistance, such as penA mosaic alleles yielding decreased susceptibility to oral extended-spectrum cephalosporins, may be a valuable method to determine treatment (3). In the same issue of Emerging Infectious Diseases, Deguchi et al. described a case of multidrug-resistant N. gonorrhoeae (4), further highlighting the urgency for the innovative approach of using molecular tests to individualize treatment regimens. An ongoing study supported by the National Institutes of Health (R21AI109005) is evaluating how a laboratory-developed molecular N. gonorrhoeae genotypic susceptibility test for ciprofloxacin enables rapid identification of effective antimicrobial drugs (5).

N. gonorrhoeae may acquire new resistance mechanisms under selection pressures imposed by use of antimicrobial drugs and horizontal gene transfer from other commensal Neisseria species resident in the human oropharynx (3). Inconsistent pharyngeal N. gonorrhoeae screening may lead to missed opportunities for treatment. A National Institutes of Health program (Antibiotic Resistance Leadership Group, award no. UM1AI104681) is ongoing to assist manufacturers in obtaining US Food and Drug Administration approval for molecular assays to detect extragenital gonococcal infections.
For nearly 8 decades, *N. gonorrhoeae* has been controllable. Continued investment in research and the development of new laboratory technology are critical in supporting an effective response to mitigate the threat of untreatable gonorrhoea.

We received funding from National Institute of Allergy and Infectious Diseases R21AI109005. C.C.B. received funding from National Institute on Drug Abuse T32 DA023356 and National Institute on Drug Abuse R01 DA037773-01A1.

References


Address for correspondence: Claire C. Bristow, University of California San Diego, 9500 Gilman Drive, La Jolla, CA 92039-0507, USA; email: cbristow@ucsd.edu

Detection of Zika Virus in Semen


DOI: http://dx.doi.org/10.3201/eid2205.160107

To the Editor: As an increasing number of autochthonous Zika virus infections are reported from several South America countries (1), we read with interest the report from Musso et al. on the potential sexual transmission of Zika virus (2). We report additional evidence for this potential route of transmission after identification of an imported case of infection into the United Kingdom.

After an outbreak alert for Zika in French Polynesia, active screening was implemented at Public Health England (Porton Down, United Kingdom). In 2014, a 68-year-old man had onset of fever, marked lethargy, and an erythematous rash 1 week after returning from the Cook Islands. Serum samples taken 3 days into the febrile illness tested negative for dengue and chikungunya viruses by real-time reverse transcription PCR (rRT-PCR). Test results for dengue virus IgM and chikungunya virus IgM also were negative; a test result for dengue virus IgG was indeterminate.

An rRT-PCR test result for Zika virus (3) was positive and indicated a crossing threshold value of 35 cycles. This low viral load, commonly observed even in the acute phase of disease (3), meant that attempts to obtain sequence data were unsuccessful. Convalescent-phase serum, urine, and semen samples were requested; only semen was positive for by rRT-PCR, at 27 and 62 days after onset of febrile illness. These results demonstrated stronger signals than those obtained in tests of the original serum sample, with crossing threshold values of 29 and 33 cycles, respectively. Zika virus-specific plaque reduction neutralization test results were positive on convalescent-phase serum samples.

Although we did not culture infectious virus from semen, our data may indicate prolonged presence of virus in semen, which in turn could indicate a prolonged potential for sexual transmission of this flavivirus. Moreover, these findings could inform decisions regarding what control methods are implemented and which specimen types are best suited for diagnostic detection.

References


Address for correspondence: Barry Atkinson, Public Health England, Porton Manor Farm Rd, Salisbury SP4 0JG, UK; email: barry.atkinson@phe.gov.uk